Salute e Benessere
Smart Medical Devices Market Size to Reach $180.4 Billion by 2033 - Strategic Growth Opportunities in Chronic Disease Management, Digital Health, and Connected Care
Cardiovascular diseases, diabetes, cancer, and respiratory illnesses account for 74% of global deaths annually (WHO).
Devices such as Abbott's FreeStyle Libre, Dexcom G7, and Medtronic's MiniMed insulin pumps highlight how digital therapeutics are enabling better outcomes and reducing hospital visits.
FDA approvals for CGM systems, smart insulin pumps, and wearable ECG monitors (Apple Watch, AliveCor) demonstrate regulatory support for innovation.
Adoption of telehealth and home-care solutions has accelerated, positioning smart medical devices as a cornerstone of next-gen healthcare delivery.
North America dominates with a 41.3% revenue share in 2024, underpinned by strong FDA pipelines and payer adoption.
Asia-Pacific is the fastest-growing region (CAGR 12.7%), fueled by digital health investments, chronic disease prevalence, and cost-effective manufacturing.
Europe benefits from MDR-driven compliance, an aging population, and partnerships between medtech startups and healthcare systems.
Collaboration opportunities between tech firms (Apple, Samsung) and medtech leaders ( Abbott , Medtronic, Philips) to expand ecosystem integration.
Demand for specialized manufacturing and connected-device platforms creates opportunities for medtech-focused contract partners.
Beyond diabetes and cardiology, growth areas include respiratory, neurology, and sleep management devices.
APAC offers cost-competitive innovation hubs, while North America leads in high-value reimbursement markets.
Products like smart wearable ECG monitors, glucose monitoring devices, and AI-powered diagnostic imaging solutions are driving this growth. The demand for continuous monitoring in chronic conditions such as diabetes and cardiac disorders has made this segment the backbone of the industry.
, valued at , are witnessing rising adoption in pain management, neurology, and sleep therapy. Smart infusion pumps, insulin delivery systems, and neuromodulation devices are creating new revenue streams by improving therapy adherence and precision dosing.
, as smart devices become central to in-patient diagnostics and acute care.
, however, are the fastest-growing category, valued at , propelled by telemedicine, remote monitoring, and patient demand for personalized healthcare solutions. Specialty clinics and ambulatory surgical centers collectively contributed
US$ 20 billion , with increasing usage of portable monitoring and therapeutic devices.
The U.S., valued at over , is the largest market for smart medical devices, driven by high healthcare spending and digital health adoption. Recent trends include:
Japan's market, valued at , is accelerating due to its aging population and government-driven healthcare digitization programs. Key highlights:
Abbott leads in , with its FreeStyle Libre continuous glucose monitoring system generating multi-billion-dollar revenues. In 2024, Abbott invested over , expanding into AI-powered cardiac monitoring solutions.
Medtronic reported , with smart therapeutic and monitoring devices forming a key growth engine. The company is at the forefront of neuromodulation and smart insulin delivery technologies, partnering with AI startups to improve device intelligence.
Apple's healthcare wearables division surpassed , with the Apple Watch playing a central role in preventive care. The launch of AI-enabled health monitoring features in 2025-including -has strengthened its leadership in consumer-driven medical devices.
Samsung's Galaxy Watch series is a market leader in Asia-Pacific for smart health monitoring. In 2025, the company integrated into its wearables, positioning itself as a hybrid between consumer electronics and medical-grade devices.
Roche remains the global leader in next-generation antibodies, particularly ADCs. In 2024, its oncology antibody portfolio generated , with Kadcyla and Polivy leading sales. The company continues to expand into bispecific antibodies targeting hematologic malignancies and is investing heavily in trispecific formats.
Amgen reported , with next-gen antibodies forming a growing share. In 2025, Amgen secured FDA approval for a bispecific antibody in multiple myeloma, strengthening its hematology pipeline. Its strategy emphasizes accelerated clinical development, global licensing partnerships, and lifecycle management of established biologics.
BMS has established itself as a leader in immuno-oncology, with a diversified pipeline of bispecific antibodies and Fc-engineered products. In 2024, BMS invested , with a significant allocation to antibody therapeutics. Its strategic acquisition of a biotech firm specializing in antibody fragments reinforced its presence in rare disease applications.
: Identify product categories and regions driving the highest growth
Track high-value therapeutic device approvals and digital health adoption trends
Evaluate how connected devices reduce costs and improve patient outcomes
https://www.datamintelligence.com/reports-subscription
– From R&D, Investment, to marketing strategies, track your global and regional rivals with ease.
– Stay ahead with detailed company profiling, SWOT analyses, and sales performance tracking.
– Daily alerts keep teams informed about product innovation, M&A activity, and competitor moves.
– Access the complete library of market reports across geographies.
– Get specific segments or competitor data added without paying extra.
– Get detailed views of market trends across the U.S., EU5, Japan , India , and LATAM.
– Make informed decisions using real-time trade intelligence.
:
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
: Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/smart-medical-devices-market-size-to-reach-180-4-billion-by-2033--strategic-growth-opportunities-in-chronic-disease-management-digital-health-and-connected-care-302561534.html